Kwality Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022


—	—	0.74×
0.67×	0.57×	1.00×
15.3%	18.1%	35.3%
0.81×	0.72×	1.33×
1.76×	1.77×	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

KPL₹3,548.00

Kwality Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA JENBURPH MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOC

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	—	—
Interest Burden (Pretax/EBIT) ×	1.00	0.57	0.67
EBIT Margin %	35.31	18.08	15.34
Asset Turnover ×	1.33	0.72	0.81
Financial Leverage (Assets/Equity) ×	—	1.77	1.76

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.